Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07711418· Phase 3· Nektar Therapeutics· Source
Completed
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis
NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
A research study to see how weekly IcoSema controls blood sugar levels when compared with daily insulin degludec/insulin aspart (IDegAsp) in people with poorly controlled type 2 diabetes (COMBINE 5)
2025-521150-42-00· Phase 3· Novo Nordisk A/S· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.
NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Terminated
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT06685835· Phase 2· Insmed Incorporated· Source
Completed
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
NCT06662539· Phase 2· Zealand Pharma· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698· Phase 2· Novo Nordisk A/S· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511360-87-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC
2023-504753-12-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Completed
A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients with Active, Mild to Moderate Ulcerative Colitis (COMPOSER-1)
2023-507376-50-00· Phase 1· Microbiotica Limited· Source
Completed
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06603077· Phase 2· Avalo Therapeutics, Inc.· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874· Phase 2· Novo Nordisk A/S· Source
Completed
A study to evaluate the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin with or without metformin
2024-511408-18-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source
Completed
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
NCT06409130· Phase 2· Novo Nordisk A/S· Source
Completed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
2023-506655-19-00· Phase 2· Genentech Inc.· Source
Terminated
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
NCT06241573· Phase 2/3· Boehringer Ingelheim· Source
Completed
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
NCT06340854· Phase 3· Novo Nordisk A/S· Source
Completed
Study of IMG-007 in Participants with Moderate to Severe Atopic Dermatitis
NCT05984784· Phase 1/2· Inmagene LLC· Source
Completed
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372· Phase 2· Novo Nordisk A/S· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT06323174· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118· Phase 3· Sanofi· Source
Completed
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Spontaneous Urticaria (CSU) to assess if it is effective and safe.
2023-504799-94-00· Phase 2· Escient Pharmaceuticals Inc.· Source
Completed
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
NCT06269107· Phase 3· Novo Nordisk A/S· Source
Completed
A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and exploratory clinical activity of NM26-2198 in healthy subjects and in patients with moderate-to-severe atopic dermatitis (AD)
NCT05859724· Phase 1· Yellow Jersey Therapeutics AG· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445· Phase 3· Incyte Corporation· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy
2022-502316-36-00· Phase 4· Myokardia Inc.· Source
Completed
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729· Phase 2· Eli Lilly and Company· Source
Completed
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· Phase 2· Janssen Research & Development, LLC· Source
Completed
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous
Urticaria
2024-514764-72-00· Phase 3· Curateq Biologics Private Limited· Source
Completed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540· Phase 3· Novo Nordisk A/S· Source
Completed
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT05936567· Phase 2· Incyte Corporation· Source
Completed
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922· Phase 2· Sanofi· Source
Completed
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
NCT05916365· Phase 3· Almirall, S.A.· Source
Completed
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
NCT05819398· Phase 2/3· Boehringer Ingelheim· Source
Completed
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate
Mavacamten in Adults with Cardiomyopathy
NCT05582395· Phase 3· Myokardia Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05620836· Phase 3· Incyte Corporation· Source
Completed
A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer
NCT05328908· Phase 3· Bristol Myers Squibb International Corporation· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
NCT05352815· Phase 3· Novo Nordisk A/S· Source
Completed
A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents and adults that have recently been diagnosed type 1 diabetes. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.
NCT05018585· Phase 3· Diamyd Medical AB· Source
Completed
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease
NCT04978493· Phase 2· Boehringer Ingelheim International GmbH· Source
Completed
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
NCT04684485· Phase 2· Sun Pharmaceutical Industries Limited· Source
Active, not recruiting
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958· Phase 3· Mirati Therapeutics Inc.· Source
Completed
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04901195· Phase 3· UCB Biopharma SRL· Source
Completed
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
NCT04718896· Phase 2· UCB Biopharma SRL· Source
Completed
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
NCT04566666· Phase 2· Sun Pharmaceutical Industries Limited· Source
Completed
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206· Phase 3· Galderma R&D· Source
Active, not recruiting
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637· Phase 3· OBI Pharma, Inc· Source
Completed
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
NCT02782663· Phase 2· AbbVie· Source